Tempest Therapeutics, Inc. Proceeds from Stock Plans
Tempest Therapeutics, Inc. (TPST) reported Proceeds from Stock Plans of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2026-08-13
- Tempest Therapeutics, Inc. proceeds from stock plans for the quarter ending 2026-06-30 was $0.00.
- Tempest Therapeutics, Inc. proceeds from stock plans for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Tempest Therapeutics, Inc. proceeds from stock plans for the quarter ending 2025-12-31 was $0.00.
- Tempest Therapeutics, Inc. proceeds from stock plans for the quarter ending 2025-09-30 was $13.00K, a 88.29% decline year-over-year.
- Tempest Therapeutics, Inc. proceeds from stock plans for fiscal 2025 was $47.00K, a 84.69% decline from fiscal 2024.
- Tempest Therapeutics, Inc. proceeds from stock plans for fiscal 2024 was $307.00K.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $13.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $13.00K derived: sum of 3 quarters · filed 2026-05-14 | $13.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $13.00K derived: sum of 2 quarters · filed 2026-03-30 | $13.00K derived: sum of 3 quarters · filed 2026-08-13 | $47.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.00K derived: sum of 2 quarters · filed 2026-08-13 | $47.00K 10-Q · filed 2025-11-05 | $46.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $34.00K 10-Q · filed 2026-08-13 | $33.00K derived: sum of 3 quarters · filed 2026-08-13 | $144.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $34.00K 10-Q · filed 2026-05-14 | $33.00K derived: sum of 2 quarters · filed 2026-05-14 | $144.00K derived: sum of 3 quarters · filed 2026-05-14 | $144.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $110.00K derived: sum of 2 quarters · filed 2026-03-30 | $110.00K derived: sum of 3 quarters · filed 2026-03-30 | $307.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $111.00K derived: sum of 2 quarters · filed 2025-11-05 | $308.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $197.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $197.00K 10-Q · filed 2025-05-13 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |